Search

Your search keyword '"Mouracade, Pascal"' showing total 4 results
Start Over Author "Mouracade, Pascal" Language undetermined
4 results on '"Mouracade, Pascal"'

1. When Partial Nephrectomy Is Unsuccessful: Understanding The Reasons For Conversion From Robotic Partial To Radical Nephrectomy At A Tertiary Referral Center

Author

Kara, Onder, Maurice, Matthew J., Mouracade, Pascal, Malkoc, Ercan, Dagenais, Julien, Nelson, Ryan J., Chaval, Jaya Sai, Stein, Robert J., Fergany, Amr, and Kaouk, Jihad H.

Subjects
body regions, technology, industry, and agriculture, human activities
Abstract

Purpose: We sought to identify the preoperative factors associated with conversion from robotic partial nephrectomy to radical nephrectomy. We report the incidence of this event.

Published
2017

3. National prospective study on the use of local haemostatic agents during partial nephrectomy

Author

Lang, Herve, Mouracade, Pascal, Gimel, Pierre, Bernhard, Jean, Pignot, Géraldine, Zini, Laurent, Crépel, Maxime, Rigaud, Jérôme, Salomon, Laurent, Bellec, Laurent, Vaessen, Christophe, Roupret, Morgan, Jung, Jean, Mourey, Eric, MARTIN, Xavier, Bigot, Pierre, Bruyere, Franck, Berger, Julien, Ansieau, Jean, Salome, Franck, Hubert, Jacques, Pfister, Christian, Trifard, François, Gigante, Marc, Baumert, Hervé, Méjean, Arnaud, Patard, Jean, Les Hôpitaux Universitaires de Strasbourg (HUS), Centre de Médecine Générale Avicenne [Cabestany], CHU de Bordeaux Pellegrin [Bordeaux], Service d'urologie [CHU Cochin], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), CHU Pontchaillou [Rennes], Centre hospitalier universitaire de Nantes (CHU Nantes), Service d'urologie [Mondor], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Service d'Urologie - Transplantation Rénale - Andrologie, Service d'Urologie [CHU Pitié-Salpêtrière], CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Hôpital du Bocage, Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Hôpital Edouard Herriot [CHU - HCL], Hospices Civils de Lyon (HCL), Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM), Service d'urologie [Tours], Centre Hospitalier Régional Universitaire de Tours (CHRU Tours)-Hôpital Bretonneau, CHU Limoges, Centre Hospitalier Emile Muller [Mulhouse] (CH E.Muller Mulhouse), Groupe Hospitalier de Territoire Haute Alsace (GHTHA), Polyclinique de Limoges - site François Chénieux [Limoges], Imagerie Adaptative Diagnostique et Interventionnelle (IADI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Service d'urologie [Rouen], CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU), Centre hospitalier Saint-Brieuc, Service d'urologie-andrologie, CHU Saint-Etienne-Université Jean Monnet [Saint-Étienne] (UJM)-Hôpital nord, Centre hospitalier Saint-Joseph [Paris], Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), AP-HP Hôpital Bicêtre (Le Kremlin-Bicêtre), UL, IADI, Département d'Urologie-Andrologie et Transplantation Rénale [CHU Toulouse], Pôle Urologie - Néphrologie - Dialyse - Transplantations - Brûlés - Chirurgie plastique - Explorations fonctionnelles et physiologiques [CHU Toulouse], Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), CHU Saint-Etienne-Université Jean Monnet - Saint-Étienne (UJM)-Hôpital nord, CHU Toulouse [Toulouse]-Hôpital de Rangueil, CHU Toulouse [Toulouse], and Université de Lorraine (UL)-Institut National de la Santé et de la Recherche Médicale (INSERM)

Subjects
Adult, Aged, 80 and over, Male, [SDV.MHEP] Life Sciences [q-bio]/Human health and pathology, Intraoperative Care, partial nephrectomy, nephron-sparing surgery, haemostatic agent, Middle Aged, Nephrectomy, Hemostatics, Young Adult, haemostasis, tissue sealants, Humans, Female, France, Prospective Studies, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology, Aged
Abstract

International audience; OBJECTIVE:To assess the use of local haemostatic agents (HAs) in a prospective multicentre large series of partial nephrectomies (PNs).PATIENTS AND METHODS:Prospective National Observational Registry on the Practices of Haemostasis in Partial Nephrectomy (NEPHRON): the study was conducted in 54 French urological centres from 1 June to 31 December 2010. In all, 570 consecutive patients undergoing a PN were enrolled in this study in a prospective manner. The data was collected prospectively via an electronic case-report form: five different sheets were included for preoperative, perioperative, postoperative and follow-up data respectively. Information related to haemostasis was analysed.RESULTS:The median patient age was 60 years and the mean (range) tumour size was 3.68 (0.19-15) cm. An HA was primarily used in 71.4% of patients, with a statistically significant difference among surgical approaches (P = 0.024). In 91.8% of cases, a single use of a HA was sufficient for achieving haemostasis. The HA was used either alone (13.9%) or in association with sutures (80.3%). One or more additional haemostatic action(s) was needed in 12.3% of the cases. When comparing patients who received a HA with those who did not receive a HA, there was no statistical difference between the groups for tumour size (P = 0.542), collecting system drainage (P = 0.538), hospital stay (P = 0.508), operation time (P = 0.169), blood loss (P = 0.387) or transfusion rate (P = 0.713).CONCLUSION:HAs are widely used by urologists during PN. Progress is needed for standardising HA application, especially for the timing of application. For the time being, the role of the HA in nephron-sparing surgery is still to be evaluated.

Published
2013
Full Text
View/download PDF

4. Review of selenium and prostate cancer prevention

Author

Lei Yang, Mouracade Pascal, and Xiao-Hou Wu

Subjects
Oncology, Male, Cancer Research, medicine.medical_specialty, Intraepithelial neoplasia, Epidemiology, business.industry, Public Health, Environmental and Occupational Health, Cancer, Prostatic Neoplasms, Malignancy, medicine.disease, Antioxidants, Clinical trial, Prostate cancer, Selenium, Erectile dysfunction, Internal medicine, Epidemiology of cancer, medicine, Animals, Humans, business, Selenium and Vitamin E Cancer Prevention Trial
Abstract

Prostate cancer is the most common malignancy in men in the United States. Surgery or radiation are sometimes unsatisfactory treatments because of the complications such as incontinence or erectile dysfunction. Selenium was found to be effective to prevent prostate cancer in the Nutritional Prevention of Cancer Trial (NPC), which motivated two other clinical trials: the Selenium and Vitamin E Cancer Prevention Trial (SELECT) and a Phase III trial of selenium to prevent prostate cancer in men with high-grade prostatic intraepithelial neoplasia. However, these two trials failed to confirm the results of the NPC trial and indicated that the selenium may not be preventive of prostate cancer. In this article we review the three clinical trials and discuss some different points which might be potential factors underlying variation in results obtained.

Published
2013

Catalog

Books, media, physical & digital resources
See catalog results